Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02096341 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

A Phase 1 study, sponsored by EpicentRx.

Terminated
Registry status
Phase 1
Development phase
2
Enrollment target

NCT02096341 is a Phase 1 study that was terminated before completion, run by EpicentRx. The registered enrollment target is 2 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02096341, a Phase 1 study, was terminated before completion, sponsored by EpicentRx.

TERMINATED
Registry status
Phase 1
Development phase
2 participants
Enrollment target

Study Summary

To investigate the dosage of RRx-001 by the subcutaneous route.

Interventions

  • DRUG RRx-001

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2014-04
Est. Completion 2016-01
Phase Phase 1

Sponsor

EpicentRx

15 total trials

What the Registry Record Tells You About NCT02096341

The ClinicalTrials.gov registry entry for NCT02096341 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EpicentRx, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which RRx-001 is the first listed.

NCT02096341 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02096341 about?

NCT02096341 is a clinical study titled "A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001". To investigate the dosage of RRx-001 by the subcutaneous route.

What is the current status of trial NCT02096341?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2014-04. Estimated completion is 2016-01.

What interventions are being tested in trial NCT02096341?

The interventions under investigation include: RRx-001 (DRUG).

Who is sponsoring clinical trial NCT02096341?

This trial is sponsored by EpicentRx, which has 15 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.